Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Rheumatoid arthritis drug can reduce the risk of deterioration in myasthenia gravis

Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control.

19 Sep 2022

Concern over two cases of monkeypox-related neurological complications in the U.S.

A new study published in the CDC's Morbidity and Mortality Weekly Report analyzed two people with encephalomyelitis associated with monkeypox disease in Colorado and DC during the current outbreak.

15 Sep 2022

Supplementary folic acid associated with higher risk of COVID-19 diagnosis and mortality

In a recent study published in the journal BMJ Open, researchers investigated the impact of folic acid supplements and methotrexate, in combination or individually, on disease severity and mortality in coronavirus disease 2019 (COVID-19) cases.

8 Sep 2022

The impact of glucocorticoid therapy on immune responses to COVID-19 vaccination or infection in rituximab-treated patients with autoimmune disorders

Researchers examined immune reactions to SARS-CoV-2)among B cell-depleted autoimmune patients who concomitantly administered glucocorticoids.

18 Jul 2022

Remdesivir resistance in renal transplant patients with long COVID-19

A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.

1 Jul 2022

Analysis finds variation in the management of mantle cell lymphoma across clinical settings

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will work to treat rheumatoid arthritis (RA) patients.

19 May 2022

Study shows how MS patients treated with Rituximab react to COVID-19 vaccination

MS patients treated with Rituximab have better responses to the COVID-19 vaccine if they have higher B cell counts.

12 May 2022

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.

21 Apr 2022

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Impact of B-cell depletion therapy on hospitalized COVID-19 patients

Researchers assessed the clinical outcomes in patients hospitalized with SARS-CoV-2 infections who were previously treated with B-cell depletion therapy.

17 Mar 2022

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

A new study examined a unique case of extended viral shedding in an immunocompromised patient that produced a series of SARS-CoV-2 immune escape mutations over a seven-month period.

8 Mar 2022

Severe COVID-19 outcomes in breakthrough infections in patients being treated with B cell depleting therapy

Scientists evaluated the incidence and severity of breakthrough SARS-CoV-2 infections among individuals with immune-mediated inflammatory diseases undergoing B cell depleting therapy.

25 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

Immunosuppressed patients can benefit from COVID-19 booster vaccination, study shows

Patients under immunosuppressive therapy, who do not respond to primary COVID-19 vaccination, have an increased risk for severe COVID-19 disease courses. Until now, it was not clear whether those patients at risk can benefit from an additional booster vaccination.

26 Jan 2022